Cencora, Inc. (COR) - Utang jangka dawa marang modal

Lambang korporat lan logo AmerisourceBergen Corporation (COR)

This chart illustrating the price evolution of the stock features Cencora, Inc. (COR), one of the key players in pharmaceutical logistics for hospitals and pharmacies. The company's model relies on massive turnover with modest margins, which ensures a colossal cash flow, although growth is constrained by warehousing costs. The current figure stands at 3.73, while revenue stability is based on the supply of oncology drugs and strict cost optimization.

AmerisourceBergen (COR) - Utang jangka dawa marang ekuitas saka 21.02.2024 nganti 30.10.2026
Barang utama Cencora

The low margins of Cencora, Inc. (COR) oncology drug distribution require the company to optimize logistics and strictly control the cost of borrowed funds. This ratio compares liabilities with a maturity of over one year to equity, determining the degree of financial autonomy and debt load risks. By analyzing long-term debt to equity, an investor assesses the business's ability to scale without compromising stability.